pharma news today glp-1 Giants Bet on Next-Generation Treatments to Sustain Growth The next phase of the

What Drugs Will Compete With Wegovy

This distinction matters enormously right now, and patients need to understand it

As our recent feasibility work shows, fragment approaches are not automatically superior for long peptides

Setting: OneFlorida+ network, consisting of 14 health systems, and ~20 million patients from 20142024

Butyrate administered in pharmacological doses (5 mM) directly to ex vivo rat islets can increase GSIS (Wang et al., 2022), but this effect might potentially be due to mechanisms unrelated to its binding to FFARs, such as on chromatin remodelling (Priyadarshini et al., 2015), found that primary isolated wild-type mouse islets secrete 50% more insulin in a GSIS assay following co-stimulation with acetate and Exendin-4 compared to FFA2 KO islets

We can't stress this enough: understanding the 'how' behind a medication is the first step toward lasting success